Table 1 Baseline patient characteristics and biomarker levels (N = 148)

Patient Characteristics

Age, median (IQR) years

58 (48, 69)

Disease Duration, median (IQR) months

40 (23, 77)

Female (percentage)

66%

IgM RF Positive (percentage)

ACPA Positive (percentage)¹

55%

Ethnicity

Caucasian

77%

Asian

5%

Afro-Caribbean

18%

TJC28, median (IQR)

0 (0, 1)

SJC28, median (IQR)

0 (0, 2)

ESR, median (IQR)

7 (4, 13)

Patient Global, median (IQR) (0–100 mm)

19 (9, 36)

DAS28-ESR, median (IQR)

2.08 (1.44, 2.77)

DAS28-CRP, median (IQR)

2.50 (2.13, 3.09)

SDAI, median (IQR)

4.1 (2, 8.23)

CDAI, median (IQR)

3.7 (1.5, 7.8)

Treatments

Methotrexate

87%

Sulfasalazine

26%

Hydroxychloroquine

30%

Leflunomide

3%

Prednisolone

2%

Combination csDMARDs

51%

Tumour necrosis factor inhibitors²

18%

Biomarker

Baseline values (median, IQR)

Time-integrated values over 6 months (median, IQR)

MBDA score (1–100)

31 (18–39)

29 (20–39)

EGF (pg/ml)

251.65 (171.13–360.64)

275.08 (173.97–358.55)

IL-6 (pg/ml)

9.73 (5.98–16.65)

10.37 (6.98–15.72)

Leptin (ng/ml)

11.78 (0.44–27.49)

MMP-1 (ng/ml)

6.80 (4.56–9.56)

7.09 (4.69–9.44)

MMP-3 (ng/ml)

25.38 (17.37–37.10)

25.23 (17.90–35.35)

Resistin (ng/ml)

7.42 (6.00–9.49)

7.61 (6.48–9.65)

SAA (μg/ml)

1.68 (0.95–3.17)

1.92 (0.87–3.97)

CRP (mg/l)

2.36 (1.10–6.14)

1.18 (2.43–5.71)

TNFR1 (ng/ml)

1.55 (1.34–1.99)

1.57 (1.38–2.00)

VCAM1 (ng/ml)

534.79 (437.82–639.31)

519.48 (431.13–610.21)

VEGF (pg/ml)

271 (177–389)

273 (189–404)

YKL-40 (ng/ml)

57.46 (36.70–92.16)

61.01 (36.82–101.60)